5-Amino-1MQ

Areas of active research — not promised effects

Each tag links to other compounds with research into that goal. Research use only: these are areas of study, not human-use claims.

Related by research scope · open each to compare

5-Amino-1MQ is an unapproved new drug substance in the United States. It is not FDA-approved for any indication, has no IND publicly on record, and is not listed on the Section 503A Bulk Drug Substances list that would permit compounding pharmacies to prepare it for patients. Sale and distribution is limited to research/laboratory use only, not for human or veterinary therapeutic use.

Transparent blend · bci-1.0 · never paid-placement

Primary name

5-Amino-1MQ

Origin

Synthetic methylquinolinium compound developed as a selective, membrane-permeable inhibitor of the metabolic enzyme nicotinamide N-methyltransferase (NNMT); originally characterized at the University of Texas Medical Branch (UTMB) by Neelakantan, Watowich, and colleagues (2018).

Registry IDs

PubChem CID

950107

CAS

685079-15-6

InChIKey

ZMJBCEIHNOWCMC-UHFFFAOYSA-O

InChIKey

ZMJBCEIHNOWCMC-UHFFFAOYSA-O

Appearance

White to off-white powder (quinolinium iodide salt form typical in research supply)

Solubility

Soluble in water and DMSO; limited solubility in non-polar solvents consistent w…

Sequence not available in current seed.

Stability: Stability under physiological conditions has not been formally published; vendor data suggest moderate aqueous stability. CAS 1421372-67-9 (as the iodide salt);

Vial sizes

50 mg

Purity grades

≥98% / ≥99%

Salt forms

Free base (primary)

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

How much research exists, and of what maturity — never a verdict on whether it works.

Mechanism of action

• 5-Amino-1MQ competitively occupies the nicotinamide-binding pocket of NNMT, blocking methyl group transfer from S-adenosylmethionine (SAM) to nicotinamide
• This inhibition conserves intracellular SAM and diverts nicotinamide toward NAD+ biosynthesis, raising NAD+ concentrations in white adipose tissue and skeletal muscle
• Elevated NAD+ activates SIRT1 and related sirtuins, which shift cellular metabolism toward increased fatty acid oxidation and reduced lipogenesis
• In diet-induced obese rodents, the net effect is reduced adipocyte size, lower white adipose mass, improved glucose tolerance, and enhanced insulin sensitivity, all without suppression of food intake (PMID 29155147; PMID 39161060)

Pharmacokinetics (ADME)

Half-life

Rat: ~3.8 h (IV), ~6.9 h (oral) — human data unavailable

Clearance

Not reported in available literature

PK–PD note: Oral bioavailability in Sprague-Dawley rats was 38.4% with Cmax ~2252 ng/mL after oral dosing. Human pharmacokinetic data have not been published. PK data derived from a single validated rat LC-MS/MS …

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Liu JR et al. Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes. Biomed Res Int. 2021;2021:9924314 (PMID 34368359) — Narrative review; states clinical trials targeting NNMT had not been reported as of 2021; cites 5-amino-1MQ as a potent small-molecule NNMT inhibitor reversing diet-induced obesity in mice
• Superpower Labs — 5-Amino-1MQ: An NNMT Inhibitor and SAM-Cycle Methylation Modulator (clinician-reviewed guide, updated July 2026) — Secondary aggregator; asserts no FDA-approved indication, no IND, no registered/completed Phase 1-3 human trials as of April 2026; evidence base described as entirely preclinical

No registered human trials found for this compound.

Status

No registered trials found

Summary (literature)

No human safety data are available. In preclinical rodent studies, 5-amino-1MQ at doses of 20 mg/kg did not produce observable adverse effects over short-term (11-day) treatment windows, and food intake was not altered (PMID 29155147). Tissue-distribution pharmacokinetics in rats…

WADA status

Not specifically listed on the WADA 2026 Prohibited List. However, S4 (Hormone and Metabolic Modulators) contains a broad 'other' clause — athletic use context …

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

p25 $1.53 · median $4.20 · p75 $7.50 · 11 researched vendors

Legit, COA-backed band: $1.30–$2.30/mg.

Value rule: don't just buy the cheapest — a price under $3/mg is a red flag. Pair price with COA and independent-test grade.

Estimated cost of research (10 mg)

Vial (best researched price)

$13

Bacteriostatic water (generic estimate)

$6

Syringes / supplies (generic estimate)

$12

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor-published purity claims of ≥99% (HPLC/LC-MS) are common across research-chemical sellers (e.g., Verified Peptides, Pure Bio Labs, True Lab Peptides, Puratek); however, no independent third-party lab test results (Janoshik/MZ Biolabs/Finnrick) were retrievable for this compound. Vendor claims are commerce-layer and not independently verified here.

Independent labs cited for this compound

No recalls, enforcement actions, criminal cases, or counterfeit/underdosing alerts specific to 5-Amino-1MQ were found in FDA, WADA, or independent lab sources reviewed. None found.

Buyer red-flag checklist

• Not FDA-approved; no NDA submitted (research-use-only labeling)
• No published human clinical trials as of sources reviewed
• Vendor purity claims (≥99%) are self-reported; no independent lab COA retrieved
• FDA 503A/503B bulk drug substance lists do not list 5-Amino-1MQ as eligible for compounding (per FDA bulks page; compound-specific Category 2 classification claimed by secondary aggregator but not verified on FDA.gov)
• No pharmacovigilance or post-market safety surveillance applies to this compound

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: No independent lab testing data (Janoshik/MZ Biolabs/Finnrick aggregates) was found for 5-Amino-1MQ; underdosing prevalence cannot be quantified.

• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Not specifically named on the 2026 WADA Prohibited List; however, as a pharmacological substance with no approval by any governmental regulatory health authority for human therapeutic use, it may fall under S0 (Non-Approved Substances). Secondary sources are split — some assert it is 'not WADA prohibited,' others assert it is banned under S0. The authoritative reading of S0 supports coverage of unapproved research chemicals.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-report selection bias toward enthusiasts
• Vendor-affiliated content (affiliate codes, sponsored reviews)
• No human clinical data; animal-model extrapolation in discourse
• Dose self-reporting unreliable (mcg vs mg confusion)
• Appearance-based authenticity heuristics (orange color) unverified

Manually researched from reddit, youtube— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

Small-molecule NNMT inhibitor that elevates cellular NAD+ and SAM in adipose tissue, reversing diet-induced obesity in rodent preclinical models without reducing food intake. Approximately 0 articles are indexed (literature last scanned 2026-05-29). US regulatory status: Research use only — not FDA-approved, not on 503A Bulks List. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet